Новостная лента

• 

  Mountain Crest Acquisition Corp. II and Better Therapeutics, Inc. Announce Registration Statement Effectiveness and Scheduled Special Meeting to Approve Business Combination on October 27, 2021

  GlobeNewsWire

  12 окт 2021 г. в 20:00

  NEW YORK and SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. II (NASDAQ: MCAD, “Mountain Crest II”), a publicly-traded special purpose acquisition company and Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that MCAD's registration statement on Form S-4 (File No. 333-255493) relating to the previously announced merger of MCAD and Better Therapeutics has been declared effective by the U.S. Securities and Exchange Commission as of October 12, 2021. MCAD also announced that it will hold its special meeting of stockholders (the “Special Meeting”) on October 27, 2021 at 10:00 am Eastern Time to, among other things, allow its stockholders to vote to approve the proposed Business Combination with Better Therapeutics. The Special Meeting will be completely virtual and conducted via live webcast at the following address https://www.cstproxy.com/mcacquisitionii/2021. Stockholders will be able to attend the meeting by using the control number that is printed on their proxy card.

• 

  Better Therapeutics to Participate in Lake Street's 5th Annual Best Ideas Growth (BIG5) Conference on September 14-15, 2021

  Business Wire

  10 сент 2021 г. в 08:00

  SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, has been invited to present at the Lake Street's 5th Annual Best Ideas Growth (BIG5) Conference, which is being held virtually on September 14-15, 2021. To receive additional information, request an invitation or to schedule a one-on-one meeting, please contact your Lake St

• 

  Better Therapeutics Expands Real-World Evidence Study Initiative With Addition of Catalyst Health Network

  Business Wire

  24 авг 2021 г. в 08:00

  SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in partnership with Catalyst Health Network (“Catalyst”), today announced the commencement of a real-world evidence study to evaluate the long-term effectiveness and healthcare utilization changes associated with the use of BT-001 for the treatment of type 2 diabetes. Catalys

• 

  Better Therapeutics and Colorado Prevention Center Clinical Research Launch Real-World Evidence Study of Prescription Digital Therapeutic for Type 2 Diabetes

  Business Wire

  29 июл 2021 г. в 15:00

  SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in partnership with Colorado Prevention Center (CPC) Clinical Research, affiliated with the University of Colorado Anschutz Medical Campus, today announced the commencement of a real-world evidence study to evaluate the long-term effectiveness and healthcare utilization chang